<DOC>
	<DOCNO>NCT01593046</DOCNO>
	<brief_summary>LAI115428 Phase I , randomize , repeat dose escalation study determine safety , tolerability , PK profile intramuscular subcutaneous injection GSK1265744 long act parenteral ( LAP ) formulation healthy subject . Subjects randomize 3 monthly dose cohort 1 quarterly dose cohort either intramuscular subcutaneous dose . In monthly dosing cohort subject receive GSK1265744 alone 2 month combination TMC278 long act parenteral ( LA ) 2 month . For quarterly dose cohort , 2 quarterly intramuscular dos GSK1265744 LAP give alone . Three dose level GSK1265744 evaluate partly combination TMC278 LA adequately characterize GSK1265744 LAP TMC278 LA safety , tolerability , PK profile . A total enrolment approximately 40 healthy subject plan study .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Repeat Dose Administration Long-Acting GSK1265744 Long-Acting TMC278 Intramuscular Subcutaneous Injections Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin great equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinically significant abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 64 year age inclusive , time signing informed consent . Females childbearing potential negative pregnancy test ( serum urine ) screen Day 21 , agree use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception six month final dose study drug . Body weight great equal 50 kg men great equal 45 kg woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . All Study subject counsel practice safer sexual practice include use effective barrier method ( e.g . male condom/spermicide ) . History bleed clot disorder include disseminate intravascular coagulation , hemophilia HenochSch√∂nlein purpura ( allergic purpura ) , hereditary hemorrhagic telangiectasia , thrombocytopenia , thrombophilia Von Willebrand 's disease . Highrisk behavior HIV infection include one follow risk factor within six month enter study ( day 1 ) : Unprotected vaginal anal sex know HIV infect person casual partner , engage sex work money drug , acquire sexually transmit disease , high risk partner currently previous six month . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy ( screen Day 21 ) drug/alcohol screen . History regular alcohol consumption within 6 month study define protocol . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Refrain use prescription nonprescription drug , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . The subject underlying skin disease disorder ( i.e . infection , inflammation , dermatitis , eczema , drug rash , drug allergy , psoriasis , food allergy , urticaria . Mild case localize acne folliculitis exclusionary . ) The subject tattoo dermatological condition overlie gluteus and/or abdominal region may interfere interpretation injection site reaction . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . History clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>GSK1265744 LAP</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>healthy subject</keyword>
	<keyword>TMC278 LA</keyword>
	<keyword>GSK1265744LAP</keyword>
	<keyword>long act retroviral</keyword>
	<keyword>HIV-1 infection</keyword>
</DOC>